Noxopharm Limited
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug… Read more
Market Cap & Net Worth: Noxopharm Limited (NOXOF)
Noxopharm Limited (PINK:NOXOF) has a market capitalization of $13.15 Million ($13.15 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #29096 globally and #9655 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Noxopharm Limited's stock price $0.05 by its total outstanding shares 292238016 (292.24 Million).
Noxopharm Limited Market Cap History: 2020 to 2025
Noxopharm Limited's market capitalization history from 2020 to 2025. Data shows change from $102.28 Million to $13.15 Million (-24.27% CAGR).
Noxopharm Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Noxopharm Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.48x
Noxopharm Limited's market cap is 5.48 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $102.28 Million | $8.28 Million | -$272.09K | 12.35x | N/A |
| 2021 | $113.97 Million | $5.61 Million | -$9.35 Million | 20.32x | N/A |
| 2022 | $38.58 Million | $5.43 Million | -$18.67 Million | 7.11x | N/A |
| 2023 | $8.77 Million | $6.01 Million | -$15.06 Million | 1.46x | N/A |
| 2024 | $13.15 Million | $2.40 Million | -$3.58 Million | 5.48x | N/A |
Competitor Companies of NOXOF by Market Capitalization
Companies near Noxopharm Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Noxopharm Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Noxopharm Limited Historical Marketcap From 2020 to 2025
Between 2020 and today, Noxopharm Limited's market cap moved from $102.28 Million to $ 13.15 Million, with a yearly change of -24.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $13.15 Million | 0.00% |
| 2024 | $13.15 Million | +50.00% |
| 2023 | $8.77 Million | -77.27% |
| 2022 | $38.58 Million | -66.15% |
| 2021 | $113.97 Million | +11.43% |
| 2020 | $102.28 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Noxopharm Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.15 Million USD |
| MoneyControl | $13.15 Million USD |
| MarketWatch | $13.15 Million USD |
| marketcap.company | $13.15 Million USD |
| Reuters | $13.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.